Jul. 16 at 5:20 PM
$ATAI $MNMD $CMPS J&J doesn't have to 'do deals out of desperation' despite facing patent cliffs: CFO
https://finance.yahoo.com/news/jj-doesnt-have-to-do-deals-out-of-desperation-despite-facing-patent-cliffs-cfo-112624430.html
"Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular, which will extend and improve lives in transformative ways,"
MM-120 for MDD 👀
ELE-101 for MDD 👀
Jay Woods, Freedom Capital Markets' chief global strategist, recently told Yahoo Finance "all eyes are on how J&J and others are going to manage their M&A strategy to account for the significant revenue losses attributed to patent expiries.
Wolk told Yahoo Finance the company is looking at a strong balance sheet, with
$20 billion on hand, plus capital deployment of
$55 billion in the last few years for large to small M&A deals. Of the
$55 billion,
$10 billion was used on 80 small deals, he said.
